Compare NextEra Energy, Inc. (NEE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs Sana Biotechnology Inc — how do they compare? NextEra Energy, Inc. trades at $86.01 (market cap $178.85B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: NextEra Energy, Inc. is far larger — about 158.3× Sana Biotechnology Inc's market cap, and NextEra Energy, Inc. pays a 2.91% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| NEE | SANA | |
|---|---|---|
Market Cap | $178.85B | $1.13B |
Sector | Utilities | Health |
52-Week High | $97.88 | $5.92 |
52-Week Low | $69.77 | $2.68 |
Enterprise Value | $286.18B | $1.05B |
Dividend Yield | 2.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $85.50, up 0.94% today, with a bearish technical signal but strong fundamentals including a 32.4% net income margin and recent earnings beats. The stock benefits from robust cash flow and a $100 billion data center partnership with Brookfield, positioning it as a key player in AI-driven power demand. Analyst consensus is bullish with a $100.40 price target, though technical indicators show resistance near $86.
Outlook is positive due to growth in electricity demand from AI data centers, supported by a 66.7% buy rating from analysts. Risks include high debt levels and volatile net cash flow. The stock offers a dividend yield of approximately 2.9%, with potential upside from execution on large-load projects.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
